Effect of vepdegestrant, a PROTAC oestrogen receptor degrader, on dabigatran and rosuvastatin pharmacokinetics in healthy participants
Authors:
Open Access
- 18 August 2025
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (12) , 3501-3510
Abstract
Aims: To evaluate the effects of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) oestrogen receptor degrader, on the pharmacokinetics of dabigatran (a P‐glycoprotein [P‐gp] substrate) and rosuvastatin (a breast cancer resistance protein [BCRP] substrate). Methods: In two phase 1, open‐label, two‐period, fixed‐sequence studies, healthy adult participants received a single oral dose of dabigatran etexilate 75 mg or rosuvastatin 10 mg alone and with a single dose of vepdegestrant 200 mg. Serial plasma samples were collected after dosing, and pharmacokinetic parameters for dabigatran and rosuvastatin were estimated by standard noncompartmental analysis. Results: Coadministration of the P‐gp substrate dabigatran etexilate with vepdegestrant increased dabigatran area under the concentration–time curve (AUC) from time 0 to infinity by 98% and maximum plasma concentration ( C max ) by 92%. Coadministration of the BCRP substrate rosuvastatin with vepdegestrant increased rosuvastatin plasma AUC from time 0 to time of the last measurable concentration by 11% and C max by 21%. Conclusions: Coadministration with vepdegestrant doubled dabigatran exposure and resulted in a minor increase (11%) in rosuvastatin exposure in humans.Keywords
This publication has 32 references indexed in Scilit:
- Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast CancerNew England Journal of Medicine, 2025
- VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancerFuture Oncology, 2024
- 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancerESMO Open, 2024
- 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort resultsESMO Open, 2024
- 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trialAnnals of Oncology, 2023
- The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein TargetsBritish Journal of Pharmacology, 2023
- The Concise Guide to PHARMACOLOGY 2023/24: EnzymesBritish Journal of Pharmacology, 2023
- PROTACs: An Emerging Therapeutic Modality in Precision MedicineCell Chemical Biology, 2020
- Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P‐gp InhibitionClinical Pharmacology & Therapeutics, 2018
- Expression and function of efflux drug transporters in the intestinePharmacology & Therapeutics, 2006